Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 May;36(3):185–190. doi: 10.1007/BF01741090

Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen

Louis M Weiner 1,✉, Gary R Hudes 1, Joanne Kitson 1, Judy Walczak 1, Perry Watts 2, Samuel Litwin 2, Peter J O'Dwyer 1
PMCID: PMC11038605  PMID: 8439979

Abstract

In a phase II clinical trial of 5-fluorouracil (5FU) plusN-(phosphonacetyl)-l-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers β2-microglobulin, HLA-DR, CD56, HNK-1, CD 16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-base-line values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.

Key words: 5-Fluorouracil, Natural killer activity, Immunosuppression, Monocytes, Immunophenotype

References

  • 1.Ades E, Hinson A, Butler L. Natural cytolytic activity in mice with natural or induced cellular defects. Cell Immunol. 1986;101:15. doi: 10.1016/0008-8749(86)90182-6. [DOI] [PubMed] [Google Scholar]
  • 2.Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or withoutN-(phosphonacetyl)-l-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol. 1988;6:1053. doi: 10.1200/JCO.1988.6.6.1053. [DOI] [PubMed] [Google Scholar]
  • 3.Ben-Efraim S, Shoval S, Ophin R. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer. 1986;22:43. doi: 10.1007/BF00205715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Berenbaum MC. The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy. 1979;25:54. doi: 10.1159/000237822. [DOI] [PubMed] [Google Scholar]
  • 5.Blomgren SE, Wolberg WH, Kisken WA. Effect of fluoropyrimidines on delayed cutaneous hypersensitivity. Cancer Res. 1965;25:977. [PubMed] [Google Scholar]
  • 6.Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21(Suppl 97):7. [PubMed] [Google Scholar]
  • 7.Freundlich B, Audolovic N. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods. 1983;62:31. doi: 10.1016/0022-1759(83)90107-2. [DOI] [PubMed] [Google Scholar]
  • 8.Goto M, Akio M, Masatoshi S, Kitano M. Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. J Exp Med. 1981;154:204. doi: 10.1084/jem.154.1.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Grem JS, Allegra CJ. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. JNCI. 1989;81:1413. doi: 10.1093/jnci/81.18.1413. [DOI] [PubMed] [Google Scholar]
  • 10.Hamilton JM, Sznol M, Friedman MA. 5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott; 1990. p. 115. [PubMed] [Google Scholar]
  • 11.Harris J, Sengar D, Stewart T, Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer. 1976;37:1058. doi: 10.1002/1097-0142(197602)37:2+<1058::aid-cncr2820370813>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  • 12.Kataoka T, Nakamura M, Iwaguchi T. In vitro inhibition of concanavalin a-induced suppressor t-cells by 5-fluorouracil. Gann. 1985;76:995. [PubMed] [Google Scholar]
  • 13.Merluzzi V, Last-Barney K, Susskind B, Faanes R. Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression. Clin Exp Immunol. 1982;50:318. [PMC free article] [PubMed] [Google Scholar]
  • 14.Mitchell M, DeConti R. Immunosuppression by 5-fluorouracil. Cancer. 1970;26:884. doi: 10.1002/1097-0142(197010)26:4<884::aid-cncr2820260422>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 15.Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JG. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352. doi: 10.1056/NEJM199002083220602. [DOI] [PubMed] [Google Scholar]
  • 16.Nordman E, Saarimaa H, Toivaneu A. The influence of 5-fluorouracil on cellular and humoral immunity in cancer patients. Cancer. 1978;41:64. doi: 10.1002/1097-0142(197801)41:1<64::aid-cncr2820410111>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  • 17.O'Dwyer PJ, Paul AR, Walzcak J, Weiner L, Litwin S, Comis R. Phase II study of biochemical modulation of 5-fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol. 1990;8:1479. doi: 10.1200/JCO.1990.8.9.1497. [DOI] [PubMed] [Google Scholar]
  • 18.Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y. Comparative studies on the immunosuppressive effect among 5′-deoxy-S-fluorouridine, Ftorafur, and 5-fluorouracil. Gann. 1980;71:190. [PubMed] [Google Scholar]
  • 19.Pross HF, Baines MT, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte mediated cytotoxicity against tumor target cell: IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 21.Sears HF, Atkinson B, Herlyn D, Ernst C, Matties J, Steplewski Z, Hayry P, Koprowski H. The use of monoclonal antibody in a phase I clinical trial of human gastrointestinal tumors. Lancet. 1982;1:762. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
  • 22.Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985;45:5910. [PubMed] [Google Scholar]
  • 23.Shih W, Baumhefner R, Tourtellotte W, Haskett C, Korn E, Fahey J. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin Exp Immunol. 1983;53:122. [PMC free article] [PubMed] [Google Scholar]
  • 24.Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma. 1986;5(Suppl 1):125. [PubMed] [Google Scholar]
  • 25.Tokuda N, Gondo H, Mayumi H, Kazuto T, Himeno K, Nomoko K. Drug-induced in vitro tolerance to allogeneic antigens. Transplantation. 1986;42:281. doi: 10.1097/00007890-198609000-00011. [DOI] [PubMed] [Google Scholar]
  • 26.Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik P. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989;7:1769. doi: 10.1200/JCO.1989.7.12.1769. [DOI] [PubMed] [Google Scholar]
  • 27.Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL, Litwin S. Phase I evaluation of combination therapy with interleukin-2 and gamma-interferon. Cancer Res. 1991;51:3910. [PubMed] [Google Scholar]
  • 28.Wiltrout RH, Taramelli D, Holden HT. Indium-111 assay of macrophage-mediated cytolysis. In: Herscowitz H, Holden HT, Bellanti JA, Gaffar A, editors. Manual of macrophage methodology. New York: Dekker; 1981. [Google Scholar]
  • 29.Wiltrout RH, Taramelli D, Holden HT. Measurement of macrophage mediated cytotoxicity against adherent and non-adherent target cells by release of111Indium-oxide. J Immunol Methods. 1981;43:319. doi: 10.1016/0022-1759(81)90180-0. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES